Apnimed's IPO

Listed Jul 31, 2026 at $16 on Nasdaq as APMD.

Offer price
$16
Market cap
$637M
Shares
12,000,000

Today 18% above its $16 offer price; its first day closed +56.3%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See APMD ranked, live

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Jul 31, 2026.

What does Apnimed do?

“We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.”
From its final prospectus (424B4), filed Jul 31, 2026
Apnimed's facts, each with its source
FactApnimed
IncorporatedDelaware, 2017From its final prospectus (424B4) of Jul 31, 2026
Employees65 full-time, as of March 31, 2026From its final prospectus (424B4) of Jul 31, 2026
Websiteapnimed.comFrom its final prospectus (424B4) of Jul 31, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Apnimed's facts, each with its source
FactApnimed
Shares offered12,000,000From the final prospectus (424B4) filed Jul 31, 2026
Offer price$16 a shareFrom the final prospectus (424B4) filed Jul 31, 2026
Raised at that price$192 millionFrom the final prospectus (424B4) filed Jul 31, 2026
Underwriters' discount$13.4 millionFrom the final prospectus (424B4) filed Jul 31, 2026
Net proceeds the company expectsAbout $174 millionFrom the final prospectus (424B4) filed Jul 31, 2026
Underwriters' option1,800,000 more sharesFrom the final prospectus (424B4) filed Jul 31, 2026
UnderwritersBofA Securities, Evercore ISI, Cantor, and LifeSci CapitalFrom the final prospectus (424B4) filed Jul 31, 2026, as its cover names them
ExchangeNasdaq Global Select Market, as APMDFrom the final prospectus (424B4) filed Jul 31, 2026
Shares outstanding after39,823,183From the final prospectus (424B4) filed Jul 31, 2026
Market cap at the offer price$637 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Apnimed's facts, each with its source
FactApnimed
Net loss$128 million, year to December 31, 2025From its final prospectus (424B4) of Jul 31, 2026, its summary financial data
Cash$46.9 million, as of March 31, 2026From its final prospectus (424B4) of Jul 31, 2026: cash and cash equivalents
Last preferred stockSeries D preferredFrom its final prospectus (424B4) of Jul 31, 2026
Raised before the IPO$389 million in private financingsFrom its final prospectus (424B4) of Jul 31, 2026

What risks does Apnimed name first?

  1. “We are a late stage clinical pharmaceutical company and have incurred significant operating losses since our inception and we expect to incur significant operating losses for the foreseeable future.”
  2. “Our existing and any future indebtedness could adversely affect our ability to operate our business.”
  3. “Even if this offering is successful, we will require substantial additional funding in order to finance operations.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Apnimed's IPO

Apnimed's IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARJul 10, 2026
Exchange registration filedexchange registration (Form 8-A), SEC EDGARJul 29, 2026
Declared effective by the SECSEC notice of effectiveness, SEC EDGARJul 30, 2026
Pricedfinal prospectus (424B4), filed Jul 31, SEC EDGARJul 30, 2026
First tradeMassive's IPO calendarJul 31, 2026
Lock-up endsfinal prospectus, SEC EDGAR: “”Jan 26, 2027

How did its first days trade?

From its daily bars, each close against its $16 offer price.

Apnimed's first sessions
DayOpenCloseFrom the
offer
Jul 31$22$25+56.3%
Aug 3$24.29$25+56.3%
Aug 4$25.01$25.71+60.7%
Aug 5$26$26.51+65.7%
Aug 6$26.78$27.88+74.3%

What is Apnimed's Quality Score?

1

Below Average

61 trading days so far; 4 of the 14 checks wait for more history.

APMD's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Apnimed IPO questions

When is Apnimed's IPO?

Listed Jul 31, 2026 at $16 on Nasdaq as APMD.

What is Apnimed's IPO price?

Apnimed's IPO priced at $16 a share, per its final prospectus of Jul 31, 2026.

How many shares is Apnimed selling?

12,000,000 shares, and the underwriters may buy 1,800,000 more, per its final prospectus (424B4).

Who are the underwriters?

BofA Securities, Evercore ISI, Cantor, and LifeSci Capital, as the prospectus's cover names them.

When does the lock-up end?

Apnimed's IPO lock-⁠up ends Jan 26, 2027. Its final prospectus says: “.”

Does Breakaway rate Apnimed?

Apnimed has a Quality Score of 1 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Apnimed's price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

  • Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
  • The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
  • The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
  • The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
  • Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and July 2026's listings.

Sources: Apnimed, Inc.'s final prospectus (424B4) of Jul 31, 2026; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Scores as of 8:31 PM ET, 15 minutes behind.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.